Christopher S. Lynch
Known title: DirectorCIK: 0001452627
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Corebridge Financial to Report Q3 2026 Results. Corebridge Financial has announced the schedule for its third-quarter 2026 financial results. Separately, industry news indicates that BHF's Shield Annuities are maintaining strong sales growth. The stock currently trades with a dividend yield of 4.43% and an average analyst target of $38.83.
Transaction History
| THC | ▼ Sell | Open Market | 3,837 | $934K | 7/27/2026 | View on chart |
| CRBG | ▲ Buy | Grant | 6,553 | $0 | 6/18/2026 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,333 | — | 5/22/2026 | View on chart |
| THC | ▼ Sell | Open Market | 8 | $1K | 8/28/2025 | View on chart |
| THC | ▼ Sell | Open Market | 3,952 | $697K | 8/19/2025 | View on chart |
| CRBG | ▲ Buy | Grant | 5,007 | $0 | 6/3/2025 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,551 | — | 5/23/2025 | View on chart |
| CRBG | ▲ Buy | Grant | 55,631 | $0 | 6/21/2024 | View on chart |
| THC | ▼ Sell | Open Market | 10,861 | $1.5M | 5/30/2024 | View on chart |
| THC | ▼ Sell | Open Market | 7,978 | $715K | 2/15/2024 | View on chart |
| CRBG | ▲ Buy | Grant | 9,981 | $0 | 6/20/2023 | View on chart |
| THC | ▲ Buy | Grant | 2,846 | $0 | 5/26/2023 | View on chart |
| CRBG | ▲ Buy | Grant | 7,858 | $0 | 9/15/2022 | View on chart |
| THC | ▲ Buy | Grant | 3,836 | $0 | 5/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets
Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets. Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.